Goto Taichiro
Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Kofu, Yamanashi 4008506, Japan.
Int J Mol Sci. 2020 Apr 26;21(9):3044. doi: 10.3390/ijms21093044.
Recent research on cancer-associated microbial communities has elucidated the interplay between bacteria, immune cells, and tumor cells; the bacterial pathways involved in the induction of carcinogenesis; and their clinical significance. Although accumulating evidence shows that a dysbiotic condition is associated with lung carcinogenesis, the underlying mechanisms remain unclear. Microorganisms possibly trigger tumor initiation and progression, presumably via the production of bacterial toxins and other pro-inflammatory factors. The purpose of this review is to discuss the basic role of the airway microbiome in carcinogenesis and the underlying molecular mechanisms, with the aim of developing anticancer strategies involving the airway microbiota. In addition, the mechanisms via which the microbiome acts as a modulator of immunotherapies in lung cancer are summarized.
近期对癌症相关微生物群落的研究已经阐明了细菌、免疫细胞和肿瘤细胞之间的相互作用；参与致癌作用诱导的细菌途径；以及它们的临床意义。尽管越来越多的证据表明生态失调状态与肺癌发生有关，但其潜在机制仍不清楚。微生物可能通过产生细菌毒素和其他促炎因子引发肿瘤的起始和进展。本综述的目的是讨论气道微生物群在致癌作用中的基本作用及其潜在分子机制，以期开发涉及气道微生物群的抗癌策略。此外，还总结了微生物群作为肺癌免疫治疗调节剂的作用机制。
